JP2014506452A - 鉄恒常性を制御するための組成物およびそれを用いる方法 - Google Patents

鉄恒常性を制御するための組成物およびそれを用いる方法 Download PDF

Info

Publication number
JP2014506452A
JP2014506452A JP2013550573A JP2013550573A JP2014506452A JP 2014506452 A JP2014506452 A JP 2014506452A JP 2013550573 A JP2013550573 A JP 2013550573A JP 2013550573 A JP2013550573 A JP 2013550573A JP 2014506452 A JP2014506452 A JP 2014506452A
Authority
JP
Japan
Prior art keywords
composition
fusion protein
fragment
derivative
derived therefrom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013550573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506452A5 (enExample
Inventor
パトリック・ギアリング
ハーバート・ワイ・リン
ジョディ・エル・バビット
トラシー・メナル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Original Assignee
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERRUMAX PHARMACEUTICALS Inc, General Hospital Corp filed Critical FERRUMAX PHARMACEUTICALS Inc
Publication of JP2014506452A publication Critical patent/JP2014506452A/ja
Publication of JP2014506452A5 publication Critical patent/JP2014506452A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
JP2013550573A 2011-01-19 2012-01-19 鉄恒常性を制御するための組成物およびそれを用いる方法 Pending JP2014506452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434405P 2011-01-19 2011-01-19
US61/434,405 2011-01-19
PCT/US2012/021829 WO2012150973A1 (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016158787A Division JP6466376B2 (ja) 2011-01-19 2016-08-12 鉄恒常性を制御するための組成物およびそれを用いる方法

Publications (2)

Publication Number Publication Date
JP2014506452A true JP2014506452A (ja) 2014-03-17
JP2014506452A5 JP2014506452A5 (enExample) 2015-03-05

Family

ID=47107987

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013550573A Pending JP2014506452A (ja) 2011-01-19 2012-01-19 鉄恒常性を制御するための組成物およびそれを用いる方法
JP2016158787A Expired - Fee Related JP6466376B2 (ja) 2011-01-19 2016-08-12 鉄恒常性を制御するための組成物およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016158787A Expired - Fee Related JP6466376B2 (ja) 2011-01-19 2016-08-12 鉄恒常性を制御するための組成物およびそれを用いる方法

Country Status (8)

Country Link
US (2) US9708379B2 (enExample)
EP (1) EP2665752B1 (enExample)
JP (2) JP2014506452A (enExample)
KR (1) KR102035357B1 (enExample)
CN (2) CN103649126B (enExample)
AU (3) AU2012251919B2 (enExample)
CA (1) CA2825163C (enExample)
WO (1) WO2012150973A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
JP6336397B2 (ja) * 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
WO2013090635A2 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
CN110381988A (zh) 2016-06-15 2019-10-25 诺华股份有限公司 使用骨形态发生蛋白6(bmp6)的抑制剂治疗疾病的方法
US20210107959A1 (en) * 2018-01-03 2021-04-15 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021150937A1 (en) * 2020-01-23 2021-07-29 The Rockefeller University Phase separation sensors and uses thereof
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
EP4359075A4 (en) * 2021-06-21 2025-05-14 Keros Therapeutics, Inc. METHODS OF USING INHIBITORS OF ACTIVIN RECEPTOR TYPE II SIGNALING

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004618A1 (en) * 2005-06-29 2007-01-04 Tomas Ganz Competitive Regulation of Hepcidin mRNA by Soluble and Cell-Associated Hemojuvelin
EP1862555A1 (en) * 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
JP2009522329A (ja) * 2006-01-05 2009-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維芽細胞活性化タンパク質に特異的な抗体分子及びそれを含む免疫複合体
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
JP2009148257A (ja) * 1999-09-07 2009-07-09 Amgen Inc 線維芽細胞増殖因子様ポリペプチド
JP2009536968A (ja) * 2006-05-12 2009-10-22 ブリストル−マイヤーズ スクイブ カンパニー 免疫モデュレート療法を受けている患者にワクチン接種する方法
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP2006298A3 (en) * 2003-04-15 2009-04-22 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
EP2349332B1 (en) * 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009148257A (ja) * 1999-09-07 2009-07-09 Amgen Inc 線維芽細胞増殖因子様ポリペプチド
US20070004618A1 (en) * 2005-06-29 2007-01-04 Tomas Ganz Competitive Regulation of Hepcidin mRNA by Soluble and Cell-Associated Hemojuvelin
JP2009522329A (ja) * 2006-01-05 2009-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維芽細胞活性化タンパク質に特異的な抗体分子及びそれを含む免疫複合体
JP2009536968A (ja) * 2006-05-12 2009-10-22 ブリストル−マイヤーズ スクイブ カンパニー 免疫モデュレート療法を受けている患者にワクチン接種する方法
EP1862555A1 (en) * 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2009074637A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
JP2017025070A (ja) 2017-02-02
US10273273B2 (en) 2019-04-30
EP2665752B1 (en) 2018-10-10
US9708379B2 (en) 2017-07-18
CN103649126B (zh) 2016-11-09
US20180044389A1 (en) 2018-02-15
AU2017201782B2 (en) 2019-01-17
AU2012251919A1 (en) 2013-08-15
EP2665752A1 (en) 2013-11-27
JP6466376B2 (ja) 2019-02-06
KR20140030134A (ko) 2014-03-11
AU2012251919A2 (en) 2014-06-12
WO2012150973A1 (en) 2012-11-08
AU2012251919B2 (en) 2016-12-15
CN107022032A (zh) 2017-08-08
CN103649126A (zh) 2014-03-19
CA2825163A1 (en) 2012-11-08
AU2017201782A1 (en) 2017-03-30
EP2665752A4 (en) 2014-09-17
AU2019202913A1 (en) 2019-05-16
KR102035357B1 (ko) 2019-10-23
WO2012150973A9 (en) 2013-01-17
CA2825163C (en) 2019-12-03
US20140199302A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
JP6466376B2 (ja) 鉄恒常性を制御するための組成物およびそれを用いる方法
US10869909B2 (en) Compositions and methods of use for treating metabolic disorders
EP3816625B1 (en) Compositions and methods for growth factor modulation
US10610568B2 (en) Compositions and methods of use for treating metabolic disorders
DK1948219T3 (en) VEGF analogs and methods for using
US10143726B2 (en) Methods of using interleukin-10 for treating diseases and disorders
KR20150114512A (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
JP2016535087A (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
AU2022202906A1 (en) Soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides and uses thereof
JP2007530055A (ja) Ｂｍｐ−３プロペプチドおよび関連する方法
WO2008068621A2 (en) Combination product with ido inhibitor and tumor targeted ifn-gamma
US8735355B2 (en) Methods of use of fragments of secreted frizzled related protein, sFRP
CA2891386A1 (en) Compositions and methods for the treatment of ectodermal dysplasia
HK1241391A1 (en) Compositions for regulating iron homeostasis and methods of using same
KR20140084191A (ko) 멜라노트란스페린으로부터 유도된 펩티드 화합물 및 이의 용도
WO2022020544A1 (en) Method of treating an inflammatory condition
HK1206260B (en) Compositions and methods of use for treating metabolic disorders
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160812

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160921

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161014